# Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

> **NCT00731679** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 623 (actual)

## Conditions studied

- Non-Constipation Irritable Bowel Syndrome

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00731679
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-08
- **Final completion:** 2009-09
- **Target enrollment:** 623 (ACTUAL)
- **Last updated:** 2019-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731679, "Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00731679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*